La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Beyond Air a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Beyond Air..

Beyond Air (NASDAQ:XAIR) Azioni, Catena delle Opzioni

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Konskie,,Poland,-,May,27,,2024:,Korn,Ferry,Company,Logo

Pre-Market Outlook

BTDR

ESEA

XAIR

Un&#39;analisi dei titoli che potrebbero influenzare la giornata di trading. Non perdere le ultime tendenze e i segnali chiave.

Futures in rialzo: i titoli da monitorare in questo mercoledì

Beyond Air Inc

News

AIFF

Firefly Neuroscience Unveils Breakthrough In Alzheimer's Detection Using Combined EEG/ERP And vMRI, Achieving Up To 87% Diagnostic Accuracy

Macquarie analyst Chad Beynon initiates coverage on Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Outperform rating and announces Price Target of $32.

Price Target

Initiation

Analyst Ratings

SRAD

Macquarie Initiates Coverage On Sportradar Gr with Outperform Rating, Announces Price Target of $32

Wells Fargo analyst Cerena Chen initiates coverage on Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) with a Overweight rating and announces Price Target of $65.

MTSR

Wells Fargo Initiates Coverage On Metsera with Overweight Rating, Announces Price Target of $65

HC Wainwright &amp; Co. analyst Scott Buck maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and lowers the price target from $5 to $3.5.

DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Lowers Price Target to $3.5

William Blair analyst Sami Corwin downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform.

Downgrades

SRPT

William Blair Downgrades Sarepta Therapeutics to Market Perform

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yeztugo&nbsp;(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">who need or want PrEP</a>.
Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative. 
The first PrEP medication, which was also developed by Gilead, was approved in the <a href="https://www.benzinga.com/pressreleases/25/06/b46004872/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months" target="_blank" rel="noreferrer noopener">U.S. in 2012</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45982235/gileads-hiv-prevention-drug-could-be-manufactured-at-shocking-low-cost-report" rel="noreferrer noopener">Gilead&#8217;s HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report</a>
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Ffull-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+1+trial&amp;index=4&amp;md5=75b8ce4877adca4271276392d97406cf" rel="noreferrer noopener">PURPOSE 1 trial</a>, data at the primary analysis showed twice-yearly subcutaneous Yeztugo demonstrated zero HIV infections among 2,134 participants in the Yeztugo group, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada&nbsp;(emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF)&nbsp;in cisgender women in sub-Saharan Africa.
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Fgilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+2+trial&amp;index=6&amp;md5=9249be8d81ad64a52dab27c8a0a16b25" rel="noreferrer noopener">PURPOSE 2 trial</a>, there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous Yeztugo group, demonstrating 99.9% of participants in the Yeztugo group did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral Truvada.
In both trials, Yeztugo, the company&#8217;s injectable HIV-1 capsid inhibitor, also demonstrated superiority in the prevention of HIV infections when compared with background HIV incidence (bHIV)&nbsp;and was generally well-tolerated, with no significant or <a target="_blank" href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" rel="noreferrer noopener">new safety concerns identified</a>.&nbsp;
In the U.S., Gilead is working closely with insurers, healthcare systems and other payers to ensure broad insurance coverage for Yeztugo. Additionally, for eligible commercially insured individuals with commercial insurance, Gilead&#8217;s Advancing Access&nbsp;Co-Pay Savings Program will reduce out-of-pocket costs to as little as zero dollars.
Gilead has submitted a marketing authorization application (MAA) and EU-Medicines for all (EU-M4all) applications with the European Medicines Agency (EMA),&nbsp;both of which the EMA has validated&nbsp;and will review under an accelerated assessment timeline.
Gilead has also filed for regulatory approval for twice-yearly lenacapavir for PrEP with authorities in Australia,&nbsp;Brazil, Canada, and&nbsp;South Africa.
<h2 class="wp-block-heading">Pricing</h2>
Citing an <a target="_blank" href="https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html" rel="noreferrer noopener">email</a> from a Gilead spokesperson, CNBC noted that Yeztugo&#8217;s annual list price in the U.S. before insurance is $28,218.
A month&#8217;s supply of Truvada and Descovy, Gilead&#8217;s daily pills for PreP, are both around $2,000 without insurance, which amounts to around $24,000 per year.
One dose of GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Apretude, which is taken once monthly for the first two months and then once every other month thereafter, costs <a target="_blank" href="https://viivuspricing.com/apretude.html" rel="noreferrer noopener">roughly $4,000</a> before insurance.
Winnie Byanyima, Executive Director of UNAIDS and United Nations Undersecretary-General, <a href="https://www.eatg.org/hiv-news/unaids-urges-gilead-to-drop-price-of-new-hiv-prevention-shot/" target="_blank" rel="noreferrer noopener">said</a>, &#8220;Lenacapavir could be the tool we need to bring new infections under control, but only if it is priced affordably and made available to everyone who could benefit.&#8221;
&#8220;UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of rollout. It is beyond comprehension how Gilead can justify a price of $28,218. If this game-changing medicine remains unaffordable, it will change nothing&#8230;,&#8221; Byanyima added.
AIDS Healthcare Foundation President Michael Weinstein sharply criticized Gilead&#8217;s outrageous pricing, <a target="_blank" href="https://www.businesswire.com/news/home/20250618031796/en/AHF-Gileads-Greed-Kills-Promise-of-Lenacapavir-for-HIV-Prevention" rel="noreferrer noopener">saying</a>, &#8220;What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead&#8217;s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV.&#8221;
Price Action: GILD stock is trading higher by 1.16% to $109.25 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44284430/merck-plans-regulatory-submission-for-two-drug-regime-for-hiv-infection-by-mid-2025" target="_blank" rel="noreferrer noopener">Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

Movers

General

GILD

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

GRRR: 21% &#x7C; <a href="https://www.benzinga.com//node/46006873">Gorilla Technology Group shares are trading higher after the company reported a year-over-year increase in revenue.</a>
&nbsp;
GPUS: 86% &#x7C; <a href="https://www.benzinga.com//node/46021982">Hyperscale Data's Bitnile.com Says It Now Accepts $TRUMP Meme Coin For Social Casino Games, To Add $PEPE In July 2025</a>
&nbsp;
JFBR: 47% &#x7C; <a href="https://www.benzinga.com//node/46022675">Jeffs' Brands and Impact Acquisitions Receive Approval from TSX Venture Exchange for Fort Products' Merger at a Valuation of up to Approximately $15 Million</a>

Trading Ideas

GPUS

GRRR

JFBR

Market-Moving News for June 20th

Wells Fargo analyst Chris Carey upgrades Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) from Equal-Weight to Overweight and raises the price target from $68 to $78.

Upgrades

MDLZ

Wells Fargo Upgrades Mondelez International to Overweight, Raises Price Target to $78

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has signed an energy storage deal with Shanghai amid trade uncertainty between Washington and Beijing.
What Happened: Tesla will set up its first grid-scale energy storage station in Shanghai, using the company's Megapack batteries, Reuters reported on Friday.
The deal involves an investment of over 4 billion yuan, or $550 million, according to the report. Tesla penned the deal with the Shanghai local government, as well as China Kangfu Leasing Co., a financial services company dealing in clean energy, among other things.
Why It Matters: The deal comes in as trade talks between the U.S. and China have returned positive news as the <a href="https://www.benzinga.com/news/politics/25/06/45854131/trump-says-hes-getting-good-reports-as-scott-bessent-led-delegation-expects-beijing-to-remove-rare-earth-export-curbs">two sides met in London</a> recently to discuss tariffs and export restrictions.
However, the truce has left some unanswered questions as the restrictions on critical rare-earth magnets for <a href="https://www.benzinga.com/news/politics/25/06/45943773/us-china-trade-truce-offers-no-relief-for-defense-supply-chains-as-china-links-rare-earths-to-chip-export-curbs-report">military-use exports</a> are still in place, which U.S. military suppliers require to manufacture fighter jets and other equipment.
Elsewhere, Tesla has been <a href="https://www.benzinga.com/markets/tech/25/06/45855123/teslas-model-y-tops-china-suv-sales-chart-in-may-with-over-24700-cars-sold">seeing a surge</a> in sales in China as the company's Model Y SUV was the best-selling SUV in China with over 24,700 sales in May.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="202" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2-1024x202.jpg" alt="" class="wp-image-955865" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2-1024x202.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2-300x59.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2-768x152.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2-1536x303.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20065839/tsla-jun-20-2025-2.jpg 1566w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46020870/elon-musks-tesla-to-expand-model-y-lineup-with-new-6-seater-version-report">Elon Musk&#8217;s Tesla To Expand Model Y Lineup With New 6-Seater Version: Report</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Elon Musk's Tesla To Build First Grid-Scale Energy Storage Site In China With $550 Million Investment

Needham analyst James Ricchiuti maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $35 to $43.

TTMI

Needham Maintains Buy on TTM Technologies, Raises Price Target to $43

Rosenblatt analyst Barton Crockett maintains Atlanta Braves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) with a Buy and raises the price target from $52 to $69.

BATRK

Rosenblatt Maintains Buy on Atlanta Braves Holdings, Raises Price Target to $69

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.61%</li>
<li>B of A Securities analyst Ken Hoexter maintained a Buy rating and increased the price target from $111 to $115 on May 16, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Oppenheimer analyst Scott Schneeberger maintained an Outperform rating and slashed the price target from $126 to $114 on April 30, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On April 29, UPS reported a quarterly consolidated revenue decline of 0.7% year-over-year to $21.546 billion, beating the consensus of $21.05 billion.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620">latest UPS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620"><img loading="lazy" decoding="async" width="911" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053347/image-307.png" alt="" class="wp-image-955780" style="width:663px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053347/image-307.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053347/image-307-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053347/image-307-768x714.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.21%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and lowered the price target from $145 to $130 on Aug. 8, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On May 7, Copa Holdings posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CPA <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620"><img loading="lazy" decoding="async" width="916" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053420/image-308.png" alt="" class="wp-image-955781" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053420/image-308.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053420/image-308-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053420/image-308-768x704.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.71%</li>
<li>Barclays analyst Manav Patnaik maintained an Equal-Weight rating and lowered the price target from $50 to $45 on April 24, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Andrew Steinerman maintained a Neutral rating and cut the price target from $65 to $47 on April 24, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On April 23, Robert Half reported worse-than-expected first-quarter financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest R<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620">HI new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620"><img loading="lazy" decoding="async" width="903" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053449/image-309.png" alt="" class="wp-image-955782" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053449/image-309.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053449/image-309-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20053449/image-309-768x720.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Markets

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields

Rosenblatt analyst Mike Genovese maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Buy and maintains $13.5 price target.

VIAV

Rosenblatt Maintains Buy on Viavi Solutions, Maintains $13.5 Price Target

Needham analyst Mayank Tandon reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $295 price target.

Reiteration

Needham Reiterates Buy on Equifax, Maintains $295 Price Target

UGI Corporation Says AmeriGas Propane To Divest Hawaii Assets To Isle Gas, Part Of Argo Infrastructure; Deal Includes 750,000 Gallons Storage, Fleet, Closes Q4 FY25

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is reportedly moving forward with plans to spin off its semiconductor division into a separate company, a step that could enable the EV maker to supply chips to other automotive firms, CnEVPost <a target="_blank" href="https://cnevpost.com/2025/06/19/nio-chip-spin-off-to-pave-way-supplying-other-automakers/" rel="noreferrer noopener">reports</a>, citing reports from local media.
The new unit will become an independent entity as part of the company&#8217;s broader strategy to diversify operations and build a standalone business model in the chip sector.
A recent spin-off report indicates the new chip-focused venture will now accept orders from external clients.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46021994/ryde-partners-with-tencent-cloud-for-enhanced-in-app-interactions" rel="noreferrer noopener">Ryde Partners With Tencent Cloud For Enhanced In-App Interactions</a>
The move reflects NIO&#8217;s ambition to tap into the growing demand for automotive semiconductors and position itself as a competitive supplier.
The newly established company, called Anhui Shengji Technology Co. Ltd., was formally registered on June 17, the report further adds.
Bai Jian, Vice President at NIO, is listed as the legal representative. With a registered capital of RMB 10 million (approximately $1.39 million), the firm will focus on chip design, distribution, and related services, according to filings from the Chinese corporate database Tianyancha.
NIO reportedly intends to maintain control of the new venture while bringing in select strategic investors, per CnEV Post.
The chip division, which currently functions as an internal unit, will now transition to an independent structure with the autonomy to collaborate with outside clients.
The spin-off news arrives as NIO accelerates its <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45981160/nio-shifts-gears-in-europe-adopts-distributor-sales-for-wider-reach" rel="noreferrer noopener">expansion into European markets</a>.
The automaker is adopting a distributor-led approach to enter Portugal, Greece, Cyprus, and Bulgaria while deepening its existing presence in Denmark. These efforts are part of a strategy to scale its global reach and boost brand visibility.
Reflecting a more favorable outlook, Goldman Sachs analyst Tina Hou recently upgraded <a target="_blank" href="https://www.benzinga.com/quote/NIO/analyst-ratings" rel="noreferrer noopener">NIO&#8217;s stock from Sell to Neutral</a>.
Meanwhile, the company has emphasized its commitment to supplier relations by speeding up payment cycles, a move it says <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/45888676/chinese-automakers-unite-nio-becomes-latest-to-promise-faster-payments" rel="noreferrer noopener">will help ensure consistent product quality and user satisfaction</a>.
Price Action: NIO shares are trading higher by 0.58% to $3.440&nbsp;premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46019223/elon-musks-x-faces-scrutiny-by-european-watchdogs-after-33-billion-acquisition-by-xai-platform-could-face-fine-ban-in-the-eu" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s X Faces Scrutiny By European Watchdogs After $33 Billion Acquisition By xAI — Platform Could Face Fine, Ban In The EU</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Equities

NIO Sets Stage For Chip Arm Spin-Off, Eyes External Clients: Report

Oaktree Capital Management co-chairman <a href="https://www.benzinga.com/topic/howard-marks" target="_blank" rel="noreferrer noopener">Howard Marks</a> revised the government interventions in Wednesday's memo titled "Shall We Repeal the Laws of Economics?"
The billionaire investor, known for his outstanding investments in distressed debt, <a target="_blank" href="https://www.oaktreecapital.com/insights/memo/more-on-repealing-the-laws-of-economics" rel="noreferrer noopener">argued</a> that economic systems operate on fundamental laws, such as supply and demand and incentives, and while these laws aren't perfect, trying to bypass them often creates greater harm than good.
<h2 class="wp-block-heading">Effects of Rent Control</h2>
"Governments are choosing winners and losers, rather than letting market forces do so."
Marks considers rent control as a typical example of a well-intended policy clashing with an economic reality. When demand for apartments exceeds supply, rising rents are inevitable. Politicians often step in to cap these increases to protect existing tenants, ensuring constituents aren't displaced and neighborhoods remain intact. This action pleases voters, helping the officials solidify their position. But this "solution" only makes a subset of people happy.
"Landlords are unhappy about not being able to charge the full rent they could charge in a free market," Marks explains, leading them to stop investing in properties or remove them from the market entirely.
Developers turn away from building new housing in these areas, fearing insufficient returns. Meanwhile, those who can afford market rents often struggle to find vacant units due to rent-controlled occupants.
The inability to monetize the benefit of cheap rent means tenants stay put, reducing mobility. Rent control suppresses both the upkeep and creation of new housing, leading to deterioration in the housing stock and limiting economic productivity.
"Governments can limit the rents landlords can charge&#8230;but they can't make developers build new ones," he concludes. A policy designed to promote fairness ends up entrenching inequality and reducing opportunity.
<h2 class="wp-block-heading">Insurance and California Regulations</h2>
"You can limit the price insurers can charge for coverage, but you can't make them provide coverage at that price."
Marks views the development of the fire insurance market in California as a case study of what happens when regulation ignores economic fundamentals. In response to rising wildfire risks, California's regulators limited the premiums insurers could charge, hoping to protect homeowners. However, Marks believes the move catastrophically backfired.
With the assistance of Perplexity AI, Marks outlined that insurers were not allowed to use forward-looking risk models, relying instead on outdated 20-year historical data, even as fires were becoming more frequent and destructive. They were also restricted from raising rates in line with increasing reinsurance costs.
As a result, companies like Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), and State Farm exited the California market or ceased writing new policies altogether. Those that remained raised premiums significantly, and some homeowners saw annual rates quadruple.
The government issued temporary moratoriums on policy cancellations, but these only applied post-disaster, not before. Consequently, many affected by the 2025 fires were underinsured or uninsured, a painful outcome of misguided regulation. The FAIR Plan, California's insurer of last resort, became overburdened and offered only limited, expensive coverage. The deeper issue was that while regulators could dictate pricing, they couldn't compel insurers to provide products that guaranteed losses.
"If a $5 million house has a 1% probability of burning down&#8230;and the regulator says you can only charge $25,000, what will you do? You don't write that policy," Marks remarks.
<h2 class="wp-block-heading">Are Tariffs the Answer?</h2>
"Progress takes countries up the curve from subsistence to prosperity, and along the way, they transition from agriculture to manufacturing to service-based economies. That happened everywhere. It wasn't just in the United States."
Turning to tariffs, Marks provides a nuanced analysis. Tariffs, often promoted as a means of protecting domestic industries and securing supply chains, are essentially taxes on imports. He concedes that tariffs might achieve goals like supporting U.S. manufacturing, reducing the trade deficit, and deterring unfair foreign practices. But the tradeoffs are substantial.
Consumers face higher prices, domestic producers may lose their incentive to innovate, and American exports can suffer as retaliatory measures take effect. Tariffs create artificial advantages that shield local industries from competition but at a cost to consumers and global efficiency.
"They impede foreign competition, enabling domestic manufacturers to sell their products even if they represent an inferior bargain," Marks notes.
Turning to the past, he references historian Niall Ferguson, who argues that industrial decline in the U.S. was inevitable due to <a target="_blank" href="https://appropriations.house.gov/sites/evo-subsites/republicans-appropriations.house.gov/files/migrated/UploadedFiles/03.28.12_CJS_-_American_Manufacturing_and_Job_Repatriation_-_Niall_Ferguson_-_Testimony.pdf" rel="noreferrer noopener">structural economic evolution</a>. As GDP rises, manufacturing employment naturally declines and shifts to services.
"We cannot go back to the 1950s&#8230;not socially, and not economically," Ferguson states. According to Marks, even if manufacturing in America is nostalgic and symbolic, it isn't economically viable on a broad scale due to significantly higher costs.
However, he acknowledges that targeted tariffs might be justified in cases of national security or against countries engaging in unfair trade practices. But attempting full-scale reshoring of production through blanket tariffs? – That tradeoff would come at the expense of domestic consumers and global welfare.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46019567/mark-cuban-says-were-he-to-become-president-for-a-day-he-would-make-these-two-simple-moves-to-overhaul-us-healthcare" target="_blank" rel="noreferrer noopener">Mark Cuban Says Were He To Become President For A Day, He Would Make These Two Simple Moves To Overhaul US Healthcare</a></li>
</ul>
Photo by Dmitry Kalinovsky via Shutterstock

Government

Regulations

Economics

Insurance

Billionaire Investor Howard Marks Says 'Even If Manufacturing In America Is Nostalgic And Symbolic, It Isn't Economically Viable'

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $2575 price target.

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $2575 Price Target

Needham analyst Mike Cikos reiterates Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Buy and maintains $75 price target.

PSTG

Needham Reiterates Buy on Pure Storage, Maintains $75 Price Target

EHang Partners With Changchun Jingyue Hi-Tech Zone To Deploy 41 EH216-S eVTOLs For Low-Altitude Use In Cold Climate Regions

Financing

Press Releases

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Earnings

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Comments

Beyond Air

Beyond Air (XAIR) Opzioni

Beyond Air (NASDAQ:XAIR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO